Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $7.1 million.

  • Beam Therapeutics' Non-cash Items rose 1496.95% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 1496.95%. This contributed to the annual value of $37.2 million for FY2024, which is 67171.24% up from last year.
  • Beam Therapeutics' Non-cash Items amounted to $7.1 million in Q3 2025, which was up 1496.95% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Non-cash Items ranged from a high of $300.6 million in Q4 2021 and a low of $1.7 million during Q2 2021
  • In the last 5 years, Beam Therapeutics' Non-cash Items had a median value of $5.8 million in 2024 and averaged $33.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 22016.13% in 2021, then plummeted by 9672.2% in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' Non-cash Items stood at $300.6 million in 2021, then plummeted by 63.07% to $111.0 million in 2022, then tumbled by 53.46% to $51.7 million in 2023, then fell by 28.02% to $37.2 million in 2024, then tumbled by 81.02% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $6.7 million for Q2 2025, and $6.3 million during Q1 2025.